Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises when Lendify, a digital lender and one of Sweden’s largest challengers to the banking sector, reaches a billion valuation in conjunction with new capital raising
Mandate

Vinge advises when Lendify, a digital lender and one of Sweden’s largest challengers to the banking sector, reaches a billion valuation in conjunction with new capital raising

September 10, 2019 M&A

Vinge has advised Lendify AB (publ) (”Lendify”) in connection with the procurement of new capital in an investment round in a total amount of approximately SEK 197 million.

The issue occurs to a valuation of Lendify of approximately SEK 1 billion (prior to the investment). The capital is intended to be used for capital adequacy and future liquidity.

Vinge’s team primarily consisted of partner Jonas Johansson together with, among others, associates Filip Öhrner, Anna Thoms and Hanna Risberg.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026